Mycophenolate mofetil

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Mycophenolate mofetil

Examples of brand names: CellCept [EU/DE]

ATC code: L04AA06

Main use (for orientation): Transplant medicine

Documented research summary

Regulatory human study: CBD 7.5 mg/kg twice daily increased MPA AUC by 35% and Cmax by 16% after MMF 1500 mg. The larger prediction at 12.5 mg/kg twice daily is a model result, not a measured value. Additional 2024 CBD + CsA + MMF case report without quantifiable information in the abstract.

Uncertainties and limitations

Case-report full text unresolved; activation and MPA inactivation may be affected differently. No class-wide extrapolation.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinically studied

Finding ID: B0003

Type of result: Positive finding / indication

Observation: Mycophenolic acid: AUC +35%, Cmax +16%.

Mechanism: UGT1A9 inhibition

Study type: Human pharmacokinetics according to product information

Context studied: CBD 7.5 mg/kg twice daily; MMF 1500 mg once; n not reported.

Clinical interpretation: Potentially high

Limitations and uncertainties: +58% AUC with higher CBD is a prediction, not a measurement.

Original sources for this finding: EPIDIOLEX (cannabidiol) oral solution – US Prescribing Information, revised 5/2026 [V5_US_LABEL_2026]; EPIDIOLEX (cannabidiol) oral solution – Prescribing Information, revised 6/2025 [CL02]

References and access status

[CA_L_D0023] MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL) TABLET, FILM COATED [CAMBER PHARMACEUTICALS, INC.]

Original source / bibliographic reference

Authors: Camber Pharmaceuticals, Inc.

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL02] EPIDIOLEX (cannabidiol) oral solution – Prescribing Information, revised 6/2025

Original source / bibliographic reference

Authors: FDA / Jazz Pharmaceuticals

Year: 2025

Source type: Regulatory product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_38212169] Drug-Drug Interaction Between Cannabidiol, Cyclosporine, and Mycophenolate Mofetil: A Case Report.

Original source / bibliographic reference

Authors: Cuñetti L, Oricchio F, Vázquez M, Peyraube R, Manzo L, Nalerio C, Curi L, Maldonado C.

Year: 2024

Source type: Journal Article; Case Reports

DOI: 10.1016/j.transproceed.2023.11.013

PMID: 38212169

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[V5_US_LABEL_2026] EPIDIOLEX (cannabidiol) oral solution – US Prescribing Information, revised 5/2026

Original source / bibliographic reference

Authors: Jazz Pharmaceuticals, Inc. / DailyMed

Year: 2026

Source type: Regulatory US product information; not an additional independent clinical study

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility